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Abstract
Background: Inadequate reporting of randomized controlled trials (RCTs) is associated with
biased estimates of treatment effects. The reporting quality of RCTs involving patients with
polycystic ovary syndrome (PCOS) is unknown. The purpose of this study was to assess the
reporting quality of RCTs involving patients with PCOS using a standardized tool based on the
Consolidated Standards of Reporting Trials (CONSORT) statement.
Methods: We searched PubMed database for English-language RCTs involving patients with
PCOS. Quality of reporting was assessed using a 24-item questionnaire based on the revised
CONSORT checklist. Reporting was evaluated overall, and for pre- and post-CONSORT periods.
RCTs on PCOS associated with fertility and non-fertility disturbances were also evaluated
separately.
Results: Nine of the 24 items were reported in less than 50% of the studies, while a significant
improvement (P < 0.05) was detected in 12 of 24 items (50%) over the two CONSORT periods.
The RCTs on PCOS with reference to fertility seem to have adhered better to CONSORT
statement than RCTs not associated to fertility.
Conclusion: There is empirical evidence of suboptimal reporting quality of RCTs in PCOS.
Endorsement of the CONSORT statement may optimize the reporting quality and enhance the
validity of research.
Background
Randomized controlled trials (RCTs) are considered the
best tool for establishing effectiveness due to minimiza-
tion of bias in evaluating new treatment strategies [1-3].
RCTs represent a key research activity with the potential to
improve the quality of health care and control costs
through careful comparison of alternative treatments
[4,5]. However, the recent flood of available information
in biomedical journals during the last years has raised
problems in a variety of areas, such as publication or selec-
tion bias and retraction of invalid literature [1,6,7].
The assessment of the methodological quality of a trial is
integrally linked with the quality of reporting; that is, the
extent to which a report provides information about the
design, conduct, and analysis of the trial [8]. Reports often
omit important methodological details. For example,
only 9% of 206 RCTs published in obstetrics and gynae-
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allocation concealment [9]. Inadequate reporting and
design are associated with biased estimates of treatment
effects. The bias associated with defects in the conduct of
RCTs varies with the type of outcome. In trials with sub-
jectively assessed outcomes, lack of adequate allocation
concealment or blinding tends to produce over-optimistic
estimates of the effect of interventions [10]. In general,
faulty reporting reflects faulty methods and a well-con-
ducted but badly-reported trial will be misclassified
[8,11,12]. Previous studies [11,13,14] indicate that
reports of low-quality RCTs, compared with reports of
higher-quality ones, overestimate the effectiveness of
interventions by about 30% across a variety of health care
conditions.
In response to concerns about quality of reporting of
RCTs, an international group of scientists and editors
developed and published in 1996, a common checklist
for items to include in reports of RCTs, known as the Con-
solidated Standards of Reporting Trials (CONSORT) state-
ment [3,15]. In 2001 the original CONSORT statement
was revised and updated to its current version, consisting
of a 22-item checklist and a four-stage flow diagram, in
order to facilitate critical appraisal and interpretation of
RCTs by providing guidance to authors about how to
improve the reporting of their trials [16-21]. Although the
content of the revised checklist is similar to that of the
original one, some previously combined items are sepa-
rated in the new version. An important addition to the
checklist is the reporting of the intention to treat (ITT)
analysis [18]. Since its publication in 1996, the CON-
SORT statement has been widely supported [19], has been
translated into several languages and has an Internet pres-
ence http://www.consort-statement.org to enhance
awareness and dissemination [17]. Its use is recom-
mended by the International Committee of Medical Jour-
nal Editors, the Council of Science Editors, and the World
Association of Medical Editors [17]; to date, more than
300 biomedical journals, have adopted these recommen-
dations [4,14-18].
There has been so far no published systematic evaluation
on the quality of RCTs involving patients with polycystic
ovary syndrome (PCOS) based on the adherence to the
CONSORT statement. Given that the reporting of funda-
mental methodological details is critical to interpret the
results of RCTs and the assessment of the quality of the
medical literature is essential, this topic was considered
sufficiently important to merit study. This particular syn-
drome was chosen due to its prevalence on women of
reproductive age and its impact on the reproductive and
cardiovascular system, necessitating a specific and tailored
treatment plan. This gynaecological disturbance, which is
diagnosed in 6 to 7% of women [22], is a heterogeneous
endocrine disorder of uncertain aetiology and a common
cause of anovulatory infertility, menstrual dysfunction,
and hirsutism [22,23]. Aim of this study was to determine
the overall reporting quality of published RCTs on PCOS
using a 24-item questionnaire based on the revised CON-
SORT checklist [17,18].
Methods
Studies Selection and Data Extraction
Literature for this review was systematically identified by
searching PubMed for papers on RCTs involving patients
with PCOS, published between January 1, 1990 and Feb-
ruary 29, 2008. The selection of this starting date was
made in order to avoid confounding factors such as edito-
rial restrictions and unavailability of electronic publish-
ing, which apply in publications, mainly, before 1990,
and to focus on the literature of RCTs that has been
informative for clinical decision-making in the field over
the last two decades. We used as filters the "Randomized
Controlled Trial" type of article, "English" language,
"Humans", "Female" gender, and as a search criterion the
following term: "polycystic ovary syndrome". Trials were
eligible if they had randomly assigned participants to at
least two treatment arms and included patients with
PCOS. All references cited in the retrieved articles were
also reviewed to identify additional published work not
indexed by PubMed. Articles were independently screened
for eligibility by the two authors, who were blinded to
each other's responses. Any discrepancies were resolved
through consensus and reference to the abstracts or arti-
cles.
The revised CONSORT checklist includes a 22-item-ques-
tionaire. However, in an attempt to determine better inter-
nal and external validity, two items from the CONSORT
checklist, namely the reporting of recruitment and follow-
up periods and the reporting of outcomes, were divided
each of them into two subcategories (recruitment and fol-
low-up, reporting of outcomes and precision of their esti-
mated effect). Hence, based on CONSORT reporting
items, we developed a 24-items data extraction sheet
(Table 1). All items were investigated in terms of whether
they were reported, not whether they were actually carried
out during the trial. Alternatives responses (apart from yes
or no) and unclear responses to each question were coded
as negative responses.
Statistical Methods
The articles were grouped in two publication periods, i.e.
1990-1995 (pre-CONSORT), and 1996-2008 (post-CON-
SORT), whereon reporting was assessed. In addition, we
compared the adherence to the CONSORT statement in
published reports of RCTs on PCOS with reference to fer-
tility with the remaining eligible papers concerning non-
fertility issues on PCOS.Page 2 of 10
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Trials 2009, 10:106 http://www.trialsjournal.com/content/10/1/106Table 1: Proportion of reporting of 24 data items in a total of 264 randomized clinical trials in polycystic ovary syndrome by 














1. Randomized in title/abstract 0.84 (222) 0.78 (21) 0.85 (201) 1.60(0.60, 4.23) 0.4
INTRODUCTION
2. Scientific background in 
introduction
0.89 (234) 0.89 (24) 0.89 (210) 0.97(0.27, 3.45) 0.99
METHODS
3. Eligibility criteria for 
participants
0.67(176) 0.19 (5) 0.72 (171) 11.40(4.14, 31.35) <0.01
4. Precise details of the 
interventions in each arm
0.99 (261) 1.00 (27) 0.99 (234) 1.22(0.06, 24.21) 0.99
5. Objectives 0.96 (254) 0.85 (23) 0.97 (231) 6.70(1.76, 25.46) 0.01
6. End-points 0.65 (171) 0.22 (6) 0.7 (165) 8.02(3.11, 20.71) <0.01
7. Sample size 0.30 (80) 0.15 (4) 0.32 (76) 2.71(0.91, 8.12) 0.08
8. Method of randomization 
(sequence generation)
0.56 (148) 0.30 (8) 0.59 (140) 3.43(1.44, 8.15) <0.01
9. Allocation concealment 0.39 (104) 0.07 (2) 0.43 (102) 9.44(2.19, 40.49) <0.01
10. Implementation of 
randomization
0.21 (56) 0.00 (0) 0.24 (56) 17.12(1.03, 285.19) <0.01
11. Blinding (masking) 0.45 (120) 0.37 (10) 0.46 (110) 1.47(0.65, 3.35) 0.42
12. Statistical methods 0.95 (252) 0.89 (24) 0.96 (228) 3.17(0.80, 12.50) 0.11
RESULTS
13. Participant flow 0.625 (165) 0.22 (6) 0.67 (159) 7.13(2.77, 18.39) <0.01
14. Periods: a. Recruitment 0.37 (98) 0.04 (1) 0.41 (97) 18.01(2.40, 134.99) <0.01
b. Follow-up 0.32 (85) 0.04 (1) 0.35 (84) 14.27(1.90, 107.07) <0.01
15. Baseline data 0.80 (212) 0.52 (14) 0.84 (198) 4.71(2.06, 10.80) <0.01
16. "Intention-to-treat" analysis 0.125 (33) 0.00 (0) 0.14 (33) 9.01(0.54, 151.26) 0.03
17. a. Outcomes and 0.99 (262) 1.00 (27) 0.99 (235) 1.71(0.08, 36.60) 0.99
b. Estimation of effects 0.54 (143) 0.44 (12) 0.55 (131) 1.54(0.69, 3.44) 0.31
18. Ancillary analyses 0.39 (103) 0.15 (4) 0.42 (99) 4.13(1.38, 12.30) 0.01Page 3 of 10
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ered important as to improve the quality of reports of
RCTs, emphasis was placed on reporting of methodologi-
cal items which are more objective, that is sample size,
method of randomization and allocation concealment,
performed statistical methods, description of baseline
data, precision of estimated effect size and reporting of ITT
analysis. Reporting of results according to the intention-
to-treat principle was analyzed in more details because
deviations from this principle can lead to over-optimistic
and biased results [24]. The ITT analysis includes all rand-
omized patients in the groups to which they were ran-
domly assigned, regardless of their compliance with the
entry criteria, the treatment they actually received, and
subsequent withdrawal from treatment or deviation from
the protocol [24,25].
Comparisons between pre- and post-CONSORT periods
were performed by calculating the odds ratio (OR), and
the respective 95% confidence interval, of reporting an
item at post-CONSORT period relative to pre-CONSORT.
Also, the association between reporting an item and pub-
lication period was tested using the Fisher' exact test. The
cutoff point for statistical significance was set at the two-
sided 0.05 level.
Results
Our search strategy identified 316 studies, of which 264
met the inclusion criteria (Fig. 1). A full list of the 264
reports that were retrieved as full-text and included in the
final analysis is found in http://biomath.med.uth.gr. Of
these articles, 27 were published in the pre-CONSORT
period (1990-1995) and 237 in the post-CONSORT
period (1996-2008). The average annual publication rate
of RCTs in PCOS increased from 5.5 publications per year
for the period 1990-1995 to 20.53 for the period 1996-
2008, representing a mean increase of approximately fif-
teen publications each year over the period under investi-
gation. The articles were retrieved from 57 journals of
which 45 have not endorsed the CONSORT statement
(Table 2). The majority of papers (59.1%) were published
in journals that are non-endorsers, including some of
wide circulation, such as Fertility and Sterility.
The consistency between the two authors for assessment
of all CONSORT items was determined using Cohen's
kappa statistics. This method involves the degree of
reviewers' agreement on whether an item was reported or
not. For calculation of κ, all items were considered
together for each paper and a good agreement between
the two reviewers was found with κ = 0.92 (0.88-0.96) in
general [26].
When the 264 RCTs are considered together, 9 of the 24
items were reported in less than 50% of the studies, such
as sample size, allocation concealment, implementation
of randomization and blinding (Table 1). Most reports,
231 of 264 (87.5%) did not give any information about
"intention-to-treat" analysis and those that report it were
conducted after the implementation of the CONSORT
statement. Similarly, implementation of randomization
was reported only in 21% (56/264) of the studies, all pub-
lished after 1995. Items that were reported in almost 90%
of the studies were the details of the interventions in each
group, the hypothesis and objectives of each study, the
statistical methods, the description of outcomes and the
summary results (interpretation, generalizability and
overall evidence).
After comparison of the two periods, a significant
improvement (P < 0.05) was detected in 12 of 24 items
(50%). These include reporting of eligibility criteria for
participants and locations where the data were collected,
hypothesis and objectives, primary and secondary out-
come measures, method of randomization (sequence
generation and allocation concealment), implementation
of randomization, participant flow, periods of recruit-
ment and follow-up, baseline data, "intention-to-treat"
analysis and ancillary analyses. The aforementioned
items, except "intention-to-treat" analysis, are much more
19. Adverse events 0.50 (132) 0.33 (9) 0.52 (123) 2.16(0.93, 5.00) 0.1
DISCUSSION
20. Interpretation of the results 0.98 (260) 1.00 (27) 0.98 (233) 0.94(0.05, 18.00) 0.99
21. Generalizability 0.92 (243) 0.89 (24) 0.92 (219) 1.52(0.42, 5.54) 0.46
22. Overall evidence 0.90 (237) 0.81 (22) 0.91 (215) 2.22(0.77, 6.45) 0.17
* CONSORT = Consolidated Standards of Reporting Trials.
† The percentage of articles reporting the CONSORT item.
¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT.
‡ P-values from Fisher's exact test for testing the association between reporting an item and publication period.
Table 1: Proportion of reporting of 24 data items in a total of 264 randomized clinical trials in polycystic ovary syndrome by 
publication period (pre- and post-CONSORT and combined)* (Continued)Page 4 of 10
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the pre-CONSORT, (see respective ORs at Table 1). An
overall improvement in reporting across all items was
detected after CONSORT statement's implementation,
except for the reporting of the precise details of the inter-
ventions, the outcomes and the interpretation of the
results that showed a minor, not statistically significant
reduction.
Among the 264 RCTs, 122 were associated with fertility
and 142 with non-fertility disturbances. The proportion
of reporting of the 24 items in these categorized trials is
displayed at Table 3 and 4. In both of them, approxi-
mately 7 of the 24 items were identified in more than 90%
of the studies. More specifically, 9 of the 24 items were
reported in less than 50% of the RCTs associated with fer-
tility, while similarly 8 of the 24 items were detected in
less than 50% of the RCTs of the other group. In both
tables the items that showed the greatest improvement
were those that were under-reported pre-CONSORT, such
as allocation concealment with OR = 20.52 (2.62, 160.49)
and method of randomization with OR = 3.67 (1.25,
10.74). The reporting in papers related to fertility in the
pre-CONSORT period was worse than those relevant to
non-fertility issues. So, the RCTs on PCOS with reference
to fertility seem to have adhered better to CONSORT
statement, with significant improvement (P < 0.05) in 13
of the 24 items, in contrast with the RCTs not associated
to fertility, which showed significant improvement in
only 6 of the 24 items.
Discussion
There are several limitations to our study. We searched
only in PubMed, which is the most common used medical
database, for the eligible RCTs and did not extent to the
Cochrane Collaboration database to combine our results
with one more sensitive search strategy for RCTs. How-
ever, a more comprehensive literature search would be
costly and time-consuming. In addition, trials which are
difficultly retrieved tend to be of lower methodological
quality and thus, bias could be introduced [27]. We con-
sidered only articles published in English, which could
lead to language bias, since authors tend to publish RCTs
in English-language journals if the results are statistically
Flow diagram of citations through the retrieval and the screening processigure 1
Flow diagram of citations through the retrieval and the screening process. RCT = randomized controlled trial; 
PCOS = Polycystic Ovary Syndrome.
Excluded: 
x Other  language (ar ticles not in English) : n=16 
x Not relevant to topic: n=7 
x Non randomized tr ials: n=10 
x Other  studies/reviews in PCOS: n=6 
References retr ieved as full text and 
included in final analysis:  n=264 
Identified duplicates: n=13
References identified in Pub med: 
PCOS: n=316
Screened for  eligibility: n=303 Page 5 of 10
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that only 5.7% of the articles captured by our search strat-
egy were published in other languages [28]. Another lim-
itation is that we did not assess the RCT methodological
quality directly, as we did not verify the information from
the authors or their protocols. Important methodological
details of the trials may not be published and thus not
evaluated. Devereaux et al. concluded through their obser-
vational study that authors of RCTs often use allocation
concealment and blinding, despite the failure to report
them [29]. The reporting of methodological aspects of
RCTs does not necessarily reflect the conduct of the trial
[30]. Additionally, although the CONSORT checklist was
revised in 2001, we decided to use the time periods 1990-
1995 and 1996-2008 because the effort of improving the
quality of RCTs began in 1996 with the original CON-
SORT statement and the items of the original checklist still
exist in the current version [17,18]. Thereupon, an imbal-
ance occurred in the amount of articles compared in the
two periods. Finally, there is not any reliable and valid
tool to assess the methodological quality of RCTs, so our
reporting quality scores are not verified. Many scales are
used to evaluate the methodological quality of RCTs, but
most of them did not follow methodological standards
during development and have not been adequately tested
for validity and reliability in the areas to which they have
been applied [31]. Despite these limitations, our results
have good internal validity, since we used an evaluation
instrument and the selection and evaluation processes
were independently performed by two reviewers. A sub-
stantial degree of agreement beyond chance for most cri-
teria was achieved, lending internal validity to our results.
The motivation for this observational study was of statis-
tical kind, thereby we compared two time periods, i.e.
1990-1995 and 1996-2008, in order to detect any
improvements of reporting of CONSORT items, guiding
on improvement of validity and quality of RCTs
[4,14,20]. We concluded that the reporting quality of
RCTs on patients with PCOS between 1990 and 2008 is
suboptimal. Even though there was a statistically signifi-
cant improvement over time in several items, such as par-
ticipant flow and baseline data, the trials were limited in
their reference of key methodologies; explicit report that
"intention-to-treat" analysis was performed occurred only
in 12.5% of the RCTs. Methods of randomization (alloca-
tion concealment and sequence generation), blinding,
and analysis according to ITT principle are essential for
internal validity so as to avoid selection, performance,
detection and attrition bias [8]. In addition, the lack of
adequate reporting of these key items has been associated
with distortions in estimates of the treatment effect
[11,13]. Our findings are in agreement with similar stud-
ies assessing the reporting quality of RCTs published in
other medical subspecialties [4,9]. Lai et al. found that
only 30% of the RCTs in the primary treatment of brain
tumors reported allocation concealment, blinding and
ITT [32]. Similarly, Dias et al. identified that 51% of the
RCTs on subfertility provided details on the randomiza-
tion method [33].
Table 2: Distribution of papers by journals
Journal Papers* Consort endorser†
Fertility and sterility 24.62% no
Human Reproduction 17.80% yes
The Journal of clinical endocrinology and metabolism 17.42% yes
Gynecological endocrinology 4.17% no
Clinical endocrinology (Oxf) 2.65% no
The Journal of reproductive medicine 2.27% no
European journal of endocrinology 1.89% no
International Journal of Gynaecology Obstetrics 1.89% no
Others (39 journals) 21.59% no
Others (10 journals) 5.68% yes
*The percentage of articles published in the journal
†According to the list "CONSORT Endorsers - Journals" provided in http://www.consort-statement.org.Page 6 of 10
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Data items Combined
1990-2008











1. Randomized in title/abstract 0.89(108) 0.76(13) 0.90(95) 2.92(0.80, 10.69) 0.11
INTRODUCTION
2. Scientific background in 
introduction
0.89(108) 0.94(16) 0.88(92) 0.44(0.05, 3.62) 0.69
METHODS
3. Eligibility criteria for 
participants
0.62(76) 0.12(2) 0.70(74) 17.90(3.86, 83.00) <0.01
4. Precise details of the 
interventions in each arm
0.98(120) 1.00(17) 0.98(103) 1.18(0.05, 25.70) 0.99
5. Objectives 0.97(118) 0.82(14) 0.99(104) 22.29(2.17, 229.28) 0.01
6. End-points 0.63(77) 0.18(3) 0.70(74) 11.14(2.99, 41.52) <0.01
7. Sample size 0.38(46) 0.12(2) 0.42(44) 5.41(1.18, 24.87) 0.03
8. Method of randomization 
(sequence generation)
0.62(76) 0.35(6) 0.67(70) 3.67(1.25, 10.74) 0.02
9. Allocation concealment 0.49(60) 0.06(1) 0.56(59) 20.52(2.62, 160.49) <0.01
10. Implementation of 
randomization
0.23(28) 0.00(0) 0.27(28) 12.87(0.75, 221.13) 0.01
11. Blinding (masking) 0.41(50) 0.47(8) 0.40(42) 0.75(0.27, 2.10) 0.61
12. Statistical methods 0.95(116) 0.88(15) 0.96(101) 3.37(0.57, 20.00) 0.19
RESULTS
13. Participant flow 0.60(73) 0.35(6) 0.64(67) 3.23(1.11, 9.44) 0.03
14. Periods: a. Recruitment 0.51(62) 0.06(1) 0.58(61) 22.18(2.84, 173.55) <0.01
b. Follow-up 0.26(32) 0.00(0) 0.30(32) 15.48(0.90, 265.24) 0.01
15. Baseline data 0.73(89) 0.47(8) 0.77(81) 3.80(1.32, 10.91) 0.02
16. "Intention-to-treat" analysis 0.15(18) 0.00(0) 0.17(18) 7.40(0.43, 128.64) 0.07
17. a. Outcomes and 0.99(121) 1.00(17) 0.99(104) 1.99(0.08, 50.85) 0.09
b. Estimation of effects 0.45(55) 0.41(7) 0.46(48) 1.20(0.43, 3.40) 0.79
18. Ancillary analyses 0.43(52) 0.12(2) 0.48(50) 6.82(1.48, 31.31) 0.01Page 7 of 10
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Trials 2009, 10:106 http://www.trialsjournal.com/content/10/1/10619. Adverse events 0.49(60) 0.24(4) 0.53(56) 3.71(1.14, 12.14) 0.04
DISCUSSION
20. Interpretation of the results 0.98(120) 1.00(17) 0.98(103) 1.18(0.05, 25.70) 0.99
21. Generalizability 0.93(113) 0.94(16) 0.92(97) 0.76(0.09, 6.47) 0.99
22. Overall evidence 0.93(113) 0.94(16) 0.92(97) 0.76(0.09, 6.47) 0.99
* CONSORT = Consolidated Standards of Reporting Trials.
† The percentage of articles reporting the CONSORT item
* CONSORT = Consolidated Standards of Reporting Trials.
† The percentage of articles reporting the CONSORT item.
¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT.
‡ P-values from Fisher's exact test for testing the association between reporting an item and publication period.
Table 3: Proportion of reporting of 24 data items in 122 randomized clinical trials in polycystic ovary syndrome associated with fertility 
by publication period (pre- and post-CONSORT and combined)* (Continued)Table 4: Proportion of reporting of 24 data items in 142 randomized clinical trials in polycystic ovary syndrome associated with non-
fertility disturbances by publication period (pre- and post-CONSORT and combined)*
Data items Combined
1990-2008











1. Randomized in title/abstract 0.80(114) 0.80(8) 0.80(106) 1.02(0.20, 5.09) 0.99
INTRODUCTION
2. Scientific background in 
introduction
0.89(126) 0.80(8) 0.89(118) 2.11(0.41, 10.92) 0.31
METHODS
3. Eligibility criteria for 
participants
0.70(100) 0.30(3) 0.73(97) 6.47(1.58, 26.40) 0.01
4. Precise details of the 
interventions in each arm
0.99(141) 1.00(10) 0.99(131) 4.17(0.16, 108.94) 0.99
5. Objectives 0.96(136) 0.90(9) 0.96(127) 2.82(0.30, 26.80) 0.36
6. End-points 0.66(94) 0.30(3) 0.69(91) 5.18(1.27, 21.04) 0.03
7. Sample size 0.24(34) 0.20(2) 0.24(32) 1.28(0.26, 6.34) 0.99
8. Method of randomization 
(sequence generation)
0.51(72) 0.20(2) 0.53(70) 4.52(0.92, 22.07) 0.05
9. Allocation concealment 0.31(44) 0.10(1) 0.33(43) 4.35(0.53, 35.43) 0.17
10. Implementation of 
randomization
0.20(28) 0.00(0) 0.21(28) 5.73(0.33, 100.73) 0.21
11. Blinding (masking) 0.49(70) 0.20(2) 0.52(68) 4.25(0.87, 20.77) 0.09
12. Statistical methods 0.96(136) 0.90(9) 0.96(127) 2.82(0.30, 26.80) 0.36Page 8 of 10
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with PCOS is also related with the fact that from the 264
papers included in the study only 40.9% came from jour-
nals that have endorsed the CONSORT statement. The
majority of the journals in the field of obstetrics and gyne-
cology are non-endorsers, including journals with rela-
tively high impact factors, such as Fertility and Sterility. In
an analysis of journals before and after the endorsement
of CONSORT statement, it was found that the descrip-
tions of the method of sequence generation, participant
flow and total CONSORT items were better after endorse-
ment of CONSORT (standardized mean difference, 3.67
items; 95% CI, 2.09-5.25) [16]. Thus, the suboptimal
reporting quality is not merely an adherence but possibly
an awareness issue of the CONSORT guidelines.
The intention of the CONSORT statement was to improve
the quality of reporting of RCTs. Studies on the quality of
reports of RCTs before and after the publication of CON-
SORT suggest that the adoption of this statement is asso-
ciated with improved reporting of RCTs [14,16]. Health
care providers depend on the reporting of methodological
factors in the reports of RCTs to allow them to determine
the validity of the trials upon which they base their clini-
cal practice and their treatment guidelines [34,35]. To
assess the strengths and limitations of RCTs, they need
and deserve to know the quality of the methods being
used [11]. With endorsement by more journals, and
greater editorial efforts to ensure that improved authors'
compliance, the CONSORT statement could begin to
yield its intended benefits [15]. Consequently, reconsider-
ation of editorial policies regarding enhanced adoption
and adherence to the CONSORT statement is an issue that
merits particular attention.
Conclusion
The knowledge gained from this study should be viewed
as an opportunity for improved adherence and increased
awareness of the CONSORT statement. The present study
provided empirical evidence of suboptimal reporting
quality of RCTs in PCOS and highlights the need for
endorsement of the CONSORT statement by journals in
the field of gynecology and obstetrics, as well as the need
for increased vigilance of authors and editors regarding
compliance of manuscripts to the CONSORT statement.
RESULTS
13. Participant flow 0.65(92) 0.00(0) 0.70(92) 47.96(2.74, 838.36) <0.01
14. Periods: a. Recruitment 0.25(36) 0.00(0) 0.27(36) 7.94(0.45, 139.05) 0.07
b. Follow-up 0.37(53) 0.10(1) 0.39(52) 5.85(0.72, 47.55) 0.09
15. Baseline data 0.87(123) 0.60(6) 0.89(117) 5.20(1.32, 20.56) 0.03
16. "Intention-to-treat" analysis 0.11(15) 0.00(0) 0.11(15) 2.77(0.15, 49.65) 0.61
17. a. Outcomes and 0.99(141) 1.00(10) 0.99(131) 4.17(0.16, 108.94) 0.99
b. Estimation of effects 0.62(88) 0.50(5) 0.63(83) 1.69(0.47, 6.15) 0.51
18. Ancillary analyses 0.36(51) 0.20(2) 0.37(49) 2.36(0.48, 11.57) 0.33
19. Adverse events 0.51(72) 0.50(5) 0.51(67) 1.03(0.28, 3.37) 0.99
DISCUSSION
20. Interpretation of the results 0.99(140) 1.00(10) 0.98(130) 2.49(0.11, 55.22) 0.99
21. Generalizability 0.92(130) 0.80(8) 0.92(122) 3.05(0.57, 16.34) 0.21
22. Overall evidence 0.87(124) 0.60(6) 0.89(118) 5.62(1.41, 22.36) 0.02
* CONSORT = Consolidated Standards of Reporting Trials.
† The percentage of articles reporting the CONSORT item
¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT.
‡ P-values from Fisher's exact test for testing the association between reporting an item and publication period.
Table 4: Proportion of reporting of 24 data items in 142 randomized clinical trials in polycystic ovary syndrome associated with non-
fertility disturbances by publication period (pre- and post-CONSORT and combined)* (Continued)Page 9 of 10
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